News | Stroke | March 02, 2016

Nexstim Receives Interim Analysis, Recommendation for Phase III Stroke Therapy Trial

Pre-specified stopping criteria for futility have been met, but Data Safety Monitoring Board recommends data collection for Navigated Brain Therapy continue

Nexstim, NICHE trial, interim analysis, Navigated Brain Therapy for stroke, NBT

March 2, 2016 — Nexstim Plc announced that the Data Safety Monitoring Board (DSMB), an independent committee of experts monitoring the Phase III stroke therapy NICHE trial, has reviewed the interim analysis data. The DSMB notes that the pre-specified stopping criteria for futility have been met and therefore the trial will not meet its primary endpoint. However, the DSMB further notes that they acknowledge that the treatments and enrolment have been completed. They recommend that the study team and subjects remain blinded and data collection be completed.

The second interim analysis on the NICHE (Navigated Inhibitory rTMS to Contralesional Hemisphere) trial using Nexstim’s Navigated Brain Therapy (NBT) was performed for 138 patients. Safety data was reviewed for all 199 patients recruited to-date; no safety concerns were observed.

Nexstim will analyze the DSMB recommendation further before deciding upon the continuation of the Phase III trial. With treatment on all patients now complete, the next phase of the trial would be to receive results from the third and final cohort’s six-month follow-up assessment.

Nexstim commenced the pivotal, randomized, sham-controlled, double-blinded multi-centre Phase III study in H1 2014 to demonstrate the effects of its NBT system on upper limb motor rehabilitation post-stroke. The two-year study is being conducted on up to 199 patients at 12 prominent rehabilitation sites in the United States. The primary objective of the study is to demonstrate a difference between the active NBT and sham groups of patients to achieve a clinically important functional improvement from baseline to six months post-treatment.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init